Approximately how much does a course of treatment with Sotoracib (AMG 510) cost and its efficacy analysis

Sotorasib (AMG 510) is the world's first approved KRAS G12C inhibitor, developed by Amgen (Amgen), and is mainly used to treat KRAS G12Cmutation-positive non-small cell lung cancer (NSCLC) patients. KRAS mutations have long been considered difficult to target, and the launch of sotorasiib marks a major breakthrough in KRAS targeted therapy, providing patients with new precision treatment options.

Currently, sotoracib is not available on the domestic market and patients cannot purchase it directly. In overseas markets, the original drugs mainly include the European version and the Hong Kong version, which are expensive, with a course of treatment costing tens of thousands of yuan. In comparison, the prices of generic drugs from Lucius and Daxiong Pharmaceuticals in Laos are more affordable. 120mg*56 tablets only cost more than 1,000 yuan, and the ingredients of the original drugs and generic drugs are basically the same, providing patients with an economically feasible choice.

Clinical studies have shown that sotorasiib has significant efficacy in patients with KRAS G12C mutated non-small cell lung cancer, with an objective response rate of approximately 37% and a disease control rate exceeding 80%. The therapeutic effect of some patients can last for more than half a year. Despite the risk of resistance, combination treatment strategies, such as combined with immunotherapy or chemotherapy, show potential to further improve efficacy.

The launch of sotoracib brings new hope to patients with KRAS mutation-driven lung cancer. Although the high price of original drugs limits the use of some patients, overseas generic drugs provide a feasible way for patients with limited financial ability. As it is launched in more regions around the world and medical insurance coverage advances, sotorasibu is expected to benefit more patients and at the same time promote the further development of KRAS targeted therapy in clinical applications.

Reference link:https://www.drugs.com